Method for predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy
Categoría
Diagnostics and Personalised Medicine
Tipo de registro
Biotech Sanitaria
Nombre socio
Producto / Servicio
Method for predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy
Tipo
Biomarkers
Diagnostic
Area terapéutica
Oncología
Enfermedades cardiovasculares y sistema circulatorio
Propiedades/Indicación
In vitro method for predicting cardiotoxicity risk in a cancer patient receiving, or susceptible to receive, anthracyclines chemotherapy 5 based on the determination of the expression levels of a combination of 10 circulating miRNAs
Fase de desarrollo
Preclinical